Amharar Youness, Curtin Vincent, Gallagher Kieran H, O'Siochru Eoin, O'Connell Peter, Healy Anne-Marie
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Eur J Pharm Sci. 2016 Jan 1;81:181-8. doi: 10.1016/j.ejps.2015.10.016. Epub 2015 Oct 19.
Co-processing an active pharmaceutical ingredient (API) with a low Tg excipient has been previously reported to be an effective strategy for preventing drug amorphisation on milling. This technique relies on the ability of the excipient to form a molecular dispersion with the amorphous API during the milling process. The presence of the excipient within the amorphous phase induces a reduction of the Tg. Hence, the molecular dispersion becomes less stable than the amorphous API alone and recrystallises upon milling. The objective of this study was to develop a screening method for the selection of suitable excipients to prevent amorphisation, based on two criteria: the Tg of the excipient and the solubility of the excipient in the amorphous API. The ability of the excipients to induce Tg reduction was first assessed by measuring the Tg of the amorphous composite by thermal analysis and comparing it with that of the pure API (griseofulvin). A predicted ability for mitigation of amorphisation upon milling was then deduced from these observations for each excipient and assessed against experimental results. The same excipients were then studied with regard to their expected solubility in another amorphous API (budesonide) by Hildebrand solubility parameter calculations in order to evaluate their capacity to form an amorphous composite with the drug. The predicted effects of the excipients on comilling were compared with the amorphous content of the processed API. The screening method as applied to both APIs showed good agreement with the experimental results and were shown to be efficient for the selection of the most appropriate excipient. This approach revealed that the two key parameters involved are the Tg of the excipient and the ability of the API to form an amorphous molecular dispersion with the excipients. This work confirms and completes our previously published results on the mitigation of the amorphisation by comilling with low Tg excipients and constitutes the first report of the use of a polymeric additive for this purpose.
先前已有报道称,将活性药物成分(API)与低玻璃化转变温度(Tg)的辅料共同加工是防止药物在研磨过程中形成无定形物的有效策略。该技术依赖于辅料在研磨过程中与无定形API形成分子分散体的能力。无定形相中辅料的存在会导致Tg降低。因此,分子分散体比单独的无定形API稳定性更低,并在研磨时重结晶。本研究的目的是基于两个标准开发一种筛选方法,以选择合适的辅料来防止无定形化,这两个标准是辅料的Tg以及辅料在无定形API中的溶解度。首先通过热分析测量无定形复合材料的Tg并将其与纯API(灰黄霉素)的Tg进行比较,来评估辅料诱导Tg降低的能力。然后根据这些观察结果推断出每种辅料在研磨时减轻无定形化的预测能力,并与实验结果进行对比评估。接着,通过希尔德布兰德溶解度参数计算研究相同的辅料在另一种无定形API(布地奈德)中的预期溶解度,以评估它们与药物形成无定形复合材料的能力。将辅料对共研磨的预测效果与加工后API的无定形含量进行比较。应用于两种API的筛选方法与实验结果显示出良好的一致性,并被证明在选择最合适的辅料方面是有效的。这种方法表明,涉及的两个关键参数是辅料的Tg以及API与辅料形成无定形分子分散体的能力。这项工作证实并完善了我们之前发表的关于通过与低Tg辅料共研磨减轻无定形化的结果,并且是首次报道为此目的使用聚合物添加剂。